Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Controlled Release 5-Fluorouracil for HCC Recurrence
NCT02523053Unknown
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of fluorouracil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Time to tumor recurrence at 5 years. Status: unknown.
02
Drugs
fluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02523053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523053.